RxDoctor Payments Data

Michael Olaciregui, MD

Internal Medicine · Milwaukee, WINPI 1811094972

Payments from drug & device makers

$3,587in general payments, 2019–2025

Across 198 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$628
  • Boehringer Ingelheim$620
  • AbbVie$544
  • Ironwood Pharmaceuticals, Inc$126
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • plus $407 from 9 others

What the payments were for

  • Food & beverage$3,587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,587 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,153
Medicare patients
12
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol155$105,200
Combivent RespimatIpratropium/Albuterol Sulfate97$55,820
JardianceEmpagliflozin61$45,611
TrulicityDulaglutide25$28,284
LinzessLinaclotide34$19,352
TradjentaLinagliptin23$16,493
MounjaroTirzepatide15$15,478
JentaduetoLinagliptin/Metformin Hcl27$15,258
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$14,809
JanuviaSitagliptin Phosphate24$13,900
Emgality PenGalcanezumab-Gnlm18$13,835
Tresiba Flextouch U-100Insulin Degludec13$6,652
Clonidine40$3,909
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,146
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm12$1,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta, Jentadueto$620$133,182208 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,143$120,009180 claims
Lilly USA, LLCTrulicity, Mounjaro$628$43,76340 claims
AbbVieLinzess$544$19,35234 claims
MerckJanuvia$110$13,90024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →